脂肪酸合酶及其抑制剂在子宫内膜癌中的研究进展

doi:10.12280/gjszjk.20230328

摘要/Abstract

摘要：

脂肪酸合酶（fatty acid synthase，FASN）是脂肪酸合成的关键酶，可催化脂质从头合成。正常组织中的脂肪酸大多来源于食物，而在子宫内膜癌细胞中脂肪酸依赖于脂质的从头合成。既往研究表明，FASN的表达与子宫内膜癌的发生、发展及预后不良相关，FASN的过表达与丝裂原细胞外激酶（mitogen extracellular kinase，MEK）/细胞外信号调节激酶（extracellular signal-regulated kinase，ERK）/丝裂原激活的蛋白激酶（mitogen-activated protein kinase，MAPK）和磷脂酰肌醇3激酶（phosphoinositide 3-kinase，PI3K）/蛋白激酶B（protein kinase B，Akt）/哺乳动物雷帕霉素靶蛋白（mammalian target of rapamycin，mTOR）信号转导通路相关。因此，特异性阻断FASN的活性可显著抑制肿瘤细胞的生长和增殖。综述子宫内膜癌中FASN的作用机制、FASN抑制剂（如C75、C93、奥利司他等）在子宫内膜癌或其他肿瘤中的研究进展，旨在为子宫内膜肿瘤的治疗提供新思路。

关键词: 脂肪酸合成酶, 酶抑制剂, 治疗, 预后, 子宫内膜肿瘤

Abstract:

Fatty acid synthase (FASN) is a key enzyme in the fatty acid synthesis that catalyzes the de novo synthesis of lipids. Most of the fatty acids are of food origin in normal tissues, while fatty acids are dependent on the de novo synthesis of lipids in endometrial cancer cells. Previous studies have shown that FASN expression is associated with the development, progression and poor prognosis of endometrial malignancies. The overexpression of FASN is correlated with mitogen extracellular kinase (MEK)/ extracellular signal-regulated kinase (ERK)/ mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/ protein kinase B (Akt)/ mammalian target of rapamycin (mTOR) signaling pathways. Specific blockade of its activity can significantly inhibit the growth and proliferation of tumor cells. We review the action of FASN and mechanism in endometrial malignancies and the progress of FASN inhibitors such as C75, C93, orlistat and so on, in endometrial cancer or other tumors, with the aim of providing new ideas for the treatment of endometrial tumors.

Key words: Fatty acid synthases, Enzyme inhibitors, Therapy, Prognosis, Endometrial neoplasms

冯雅茹, 李雪, 张慧英. 脂肪酸合酶及其抑制剂在子宫内膜癌中的研究进展[J]. 国际生殖健康/计划生育杂志, 2024, 43(1): 79-82.

FENG Ya-ru, LI Xue, ZHANG Hui-ying. Fatty Acid Synthase and Its Inhibitors in Endometrial Cancer[J]. Journal of International Reproductive Health/Family Planning, 2024, 43(1): 79-82.

参考文献 29

[1]	Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(9):860-877. doi: 10.1016/j.annonc.2022.05.009. pmid: 35690222
[2]	郑荣寿, 张思维, 孙可欣, 等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2023, 45(3):212-220. doi: 10.3760/cma.j.cn112152-20220922-00647.
[3]	Ding S, Madu CO, Lu Y. The Impact of Hormonal Imbalances Associated with Obesity on the Incidence of Endometrial Cancer in Postmenopausal Women[J]. J Cancer, 2020, 11(18):5456-5465. doi: 10.7150/jca.47580. pmid: 32742493
[4]	Bian X, Liu R, Meng Y, et al. Lipid metabolism and cancer[J]. J Exp Med, 2021, 218(1):e20201606. doi: 10.1084/jem.20201606.
[5]	Vanauberg D, Schulz C, Lefebvre T. Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies[J]. Oncogenesis, 2023, 12(1):16. doi: 10.1038/s41389-023-00460-8. pmid: 36934087
[6]	Fhu CW, Ali A. Fatty Acid Synthase: An Emerging Target in Cancer[J]. Molecules, 2020, 25(17):3935. doi: 10.3390/molecules25173935.
[7]	Wu ZS, Huang SM, Wang YC. Palmitate Enhances the Efficacy of Cisplatin and Doxorubicin against Human Endometrial Carcinoma Cells[J]. Int J Mol Sci, 2021, 23(1):80. doi: 10.3390/ijms23010080.
[8]	Zhang J, Song Y, Shi Q, et al. Research progress on FASN and MGLL in the regulation of abnormal lipid metabolism and the relationship between tumor invasion and metastasis[J]. Front Med, 2021, 15(5):649-656. doi: 10.1007/s11684-021-0830-0.
[9]	Chi C, Harth L, Galera MR, et al. Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL[J]. Cancers(Basel), 2022, 14(18):4491. doi: 10.3390/cancers14184491.
[10]	Mozihim AK, Chung I, Said N, et al. Reprogramming of Fatty Acid Metabolism in Gynaecological Cancers: Is There a Role for Oestradiol?[J]. Metabolites, 2022, 12(4):350. doi: 10.3390/metabo12040350.
[11]	Tsuji T, Yoshinaga M, Togami S, et al. Fatty acid synthase expression and clinicopathological findings in endometrial cancer[J]. Acta Obstet Gynecol Scand, 2004, 83(6):586-590. doi: 10.1111/j.0001-6349.2004.00511.x.
[12]	Anagnostou E, Miliaras D, Meditskou S, et al. Immunohistochemical investigation of metabolic markers fatty acid synthase (FASN) and glucose transporter 1 (GLUT1) in normal endometrium, endometrial hyperplasia, and endometrial malignancy[J]. Hippokratia, 2017, 21(4):169-174. pmid: 30944506
[13]	Butler LM, Perone Y, Dehairs J, et al. Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention[J]. Adv Drug Deliv Rev, 2020, 159:245-293. doi: 10.1016/j.addr.2020.07.013.
[14]	Sebastiani V, Visca P, Botti C, et al. Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma[J]. Gynecol Oncol, 2004, 92(1):101-105. doi: 10.1016/j.ygyno.2003.10.027. pmid: 14751145
[15]	Rahman MT, Nakayama K, Ishikawa M, et al. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer[J]. Oncology, 2013, 84(3):166-173. doi: 10.1159/000342967. pmid: 23306391
[16]	Raab S, Lefebvre T. Fatty acid synthase, a "multi-FASet" enzyme[J]. Med Sci(Paris), 2022, 38(5):445-452. doi: 10.1051/medsci/2022062.
[17]	Qu H, Shan K, Tang C, et al. A novel small-molecule fatty acid synthase inhibitor with antitumor activity by cell cycle arrest and cell division inhibition[J]. Eur J Med Chem, 2021, 219:113407. doi: 10.1016/j.ejmech.2021.113407.
[18]	Singh S, Karthikeyan C, Moorthy N. Recent Advances in the Development of Fatty Acid Synthase Inhibitors as Anticancer Agents[J]. Mini Rev Med Chem, 2020, 20(18):1820-1837. doi: 10.2174/1389557520666200811100845.
[19]	Menendez JA, Peirce SK, Papadimitropoulou A, et al. Progesterone receptor isoform-dependent cross-talk between prolactin and fatty acid synthase in breast cancer[J]. Aging(Albany NY), 2020, 12(24):24671-24692. doi: 10.18632/aging.202289.
[20]	Pandey PR, Liu W, Xing F, et al. Anti-cancer drugs targeting fatty acid synthase (FAS)[J]. Recent Pat Anticancer Drug Discov, 2012, 7(2):185-197. doi: 10.2174/157489212799972891. pmid: 22338595
[21]	Chaturvedi S, Biswas M, Sadhukhan S, et al. Role of EGFR and FASN in breast cancer progression[J]. J Cell Commun Signal, 2023, 17(4):1249-1282. doi: 10.1007/s12079-023-00771-w.
[22]	Wysham WZ, Roque DR, Han J, et al. Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines[J]. Target Oncol, 2016, 11(6):763-769. doi: 10.1007/s11523-016-0442-9. pmid: 27188391
[23]	Xu G, Zhao Z, Wysham WZ, et al. Orlistat exerts anti-obesity and anti-tumorigenic effects in a transgenic mouse model of endometrial cancer[J]. Front Oncol, 2023, 13:1219923. doi: 10.3389/fonc.2023.1219923.
[24]	Çetinkaya M, Baran Y. Therapeutic Potential of Luteolin on Cancer[J]. Vaccines(Basel), 2023, 11(3):554. doi: 10.3390/vaccines11030554.
[25]	Prasher P, Sharma M, Singh SK, et al. Luteolin: a flavonoid with a multifaceted anticancer potential[J]. Cancer Cell Int, 2022, 22(1):386. doi: 10.1186/s12935-022-02808-3. pmid: 36482329
[26]	Kciuk M, Alam M, Ali N, et al. Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications[J]. Molecules, 2023, 28(13):5246.doi: 10.3390/molecules28135246.
[27]	Oh JE, Jung BH, Park J, et al. Deciphering Fatty Acid Synthase Inhibition-Triggered Metabolic Flexibility in Prostate Cancer Cells through Untargeted Metabolomics[J]. Cells, 2020, 9(11):2447. doi: 10.3390/cells9112447.
[28]	Batchuluun B, Pinkosky SL, Steinberg GR. Lipogenesis inhibitors: therapeutic opportunities and challenges[J]. Nat Rev Drug Discov, 2022, 21(4):283-305. doi: 10.1038/s41573-021-00367-2. pmid: 35031766
[29]	Bruce SF, Wu S, Ribeiro JR, et al. HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis[J]. Gynecol Oncol, 2023, 172:98-105. doi: 10.1016/j.ygyno.2023.03.008. pmid: 37003074